BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang X, Qiang Q, Li N, Feng P, Wei W, Hölscher C. Neuroprotective Mechanisms of Glucagon-Like Peptide-1-Based Therapies in Ischemic Stroke: An Update Based on Preclinical Research. Front Neurol 2022;13:844697. [PMID: 35370875 DOI: 10.3389/fneur.2022.844697] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Hammoud R, Drucker DJ. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nat Rev Endocrinol 2022. [PMID: 36509857 DOI: 10.1038/s41574-022-00783-3] [Reference Citation Analysis]
2 Singh DD, Shati AA, Alfaifi MY, Elbehairi SEI, Han I, Choi EH, Yadav DK. Development of Dementia in Type 2 Diabetes Patients: Mechanisms of Insulin Resistance and Antidiabetic Drug Development. Cells 2022;11. [PMID: 36497027 DOI: 10.3390/cells11233767] [Reference Citation Analysis]
3 Su Q, Chen Q, Li Z, Zhao J, Li L, Xu L, Yang B, Liu C. Multi-omics analysis reveals GABAergic dysfunction after traumatic brainstem injury in rats. Front Neurosci 2022;16:1003300. [PMID: 36507346 DOI: 10.3389/fnins.2022.1003300] [Reference Citation Analysis]
4 Yang X, Feng P, Ji R, Ren Y, Wei W, Hölscher C. Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson's disease. Expert Opin Ther Targets 2022. [PMID: 35584372 DOI: 10.1080/14728222.2022.2079492] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]